These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38366706)

  • 1. The association between KRAS and histopathological growth patterns and the impact on resection margins around vasculature and bile ducts in colorectal liver metastases.
    Wong P; Wong GYM; Toon CW; Chapuis P; Hugh TJ
    ANZ J Surg; 2024 Apr; 94(4):560-565. PubMed ID: 38366706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical appraisal of surgical margins according to KRAS status in liver resection for colorectal liver metastases: Should surgical strategy be influenced by tumor biology?
    Rhaiem R; Duramé A; Primavesi F; Dorcaratto D; Syn N; Rodríguez ÁH; Dupré A; Piardi T; Fernández GB; Villaverde AP; Rodríguez Sanjuán JC; Santiago RF; Fernández-Moreno MC; Ferret G; Ben SL; Suárez Muñoz MÁ; Perez-Alonso AJ; Koh YX; Jones R; Martín-Pérez E; Kianmanesh R; Di Martino M
    Surgery; 2024 Jul; 176(1):124-133. PubMed ID: 38519408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS Mutation Predicted More Mirometastases and Closer Resection Margins in Patients with Colorectal Cancer Liver Metastases.
    Zhang Q; Peng J; Ye M; Weng W; Tan C; Ni S; Huang D; Sheng W; Wang L
    Ann Surg Oncol; 2020 Apr; 27(4):1164-1173. PubMed ID: 31720935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis.
    Tosi F; Magni E; Amatu A; Mauri G; Bencardino K; Truini M; Veronese S; De Carlis L; Ferrari G; Nichelatti M; Sartore-Bianchi A; Siena S
    Clin Colorectal Cancer; 2017 Sep; 16(3):e153-e163. PubMed ID: 28216246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
    Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
    Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
    Margonis GA; Kim Y; Sasaki K; Samaha M; Amini N; Pawlik TM
    Cancer; 2016 Sep; 122(17):2698-707. PubMed ID: 27244540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anatomical Resections Improve Disease-free Survival in Patients With KRAS-mutated Colorectal Liver Metastases.
    Margonis GA; Buettner S; Andreatos N; Sasaki K; Ijzermans JNM; van Vugt JLA; Pawlik TM; Choti MA; Cameron JL; He J; Wolfgang CL; Weiss MJ
    Ann Surg; 2017 Oct; 266(4):641-649. PubMed ID: 28657938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of resection margin and KRAS status on outcomes after resection of colorectal liver metastases.
    Hatta AAZ; Pathanki AM; Hodson J; Sutcliffe RP; Marudanayagam R; Roberts KJ; Chatzizacharias N; Isaac J; Muiesan P; Taniere P; Mirza DF; Dasari BVM
    HPB (Oxford); 2021 Jan; 23(1):90-98. PubMed ID: 32417170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does KRAS mutation status impact the risk of local recurrence after R1 vascular resection for colorectal liver metastasis? An observational cohort study.
    Procopio F; Viganò L; Cimino M; Donadon M; Del Fabbro D; Torzilli G
    Eur J Surg Oncol; 2020 May; 46(5):818-824. PubMed ID: 31839435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.
    Margonis GA; Kim Y; Spolverato G; Ejaz A; Gupta R; Cosgrove D; Anders R; Karagkounis G; Choti MA; Pawlik TM
    JAMA Surg; 2015 Aug; 150(8):722-9. PubMed ID: 26038887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of KRAS mutational status on long-term survival according to the timing of colorectal liver metastases.
    Sakai N; Furukawa K; Takayashiki T; Kuboki S; Takano S; Ohtsuka M
    BMC Cancer; 2021 Apr; 21(1):412. PubMed ID: 33858364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From bench to bedside: Clinical implications of KRAS status in patients with colorectal liver metastasis.
    Andreatos N; Ronnekleiv-Kelly S; Margonis GA; Sasaki K; Gani F; Amini N; Wilson A; Pawlik TM
    Surg Oncol; 2016 Sep; 25(3):332-8. PubMed ID: 27566041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location.
    Sasaki K; Margonis GA; Wilson A; Kim Y; Buettner S; Andreatos N; Gani F; Amini N; Spolverato G; Pawlik TM
    Ann Surg Oncol; 2016 Oct; 23(11):3736-3743. PubMed ID: 27352204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of primary cancer features on behaviour of colorectal liver metastases and survival after hepatectomy.
    Cucchetti A; Russolillo N; Johnson P; Tarchi P; Ferrero A; Cucchi M; Serenari M; Ravaioli M; de Manzini N; Cescon M; Ercolani G
    BJS Open; 2019 Apr; 3(2):186-194. PubMed ID: 30957066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of anatomical liver resection on patient survival in KRAS-wild-type colorectal liver metastasis: A multicenter retrospective study.
    Kawai T; Ishii T; Uchida Y; Sato A; Naito S; Kitaguchi K; Komatsubara T; Nakamura I; Ogiso S; Fukumitsu K; Seo S; Fujikawa T; Yasuchika K; Hirose T; Zaima M; Taura K; Hatano E; Terajima H
    Surgery; 2022 Oct; 172(4):1133-1140. PubMed ID: 35965146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases.
    Margonis GA; Spolverato G; Kim Y; Karagkounis G; Choti MA; Pawlik TM
    Ann Surg Oncol; 2015 Dec; 22(13):4158-65. PubMed ID: 26077912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant Hepatic Artery Infusion Chemotherapy is Associated With Improved Survival Regardless of KRAS Mutation Status in Patients With Resected Colorectal Liver Metastases: A Retrospective Analysis of 674 Patients.
    Gholami S; Kemeny NE; Boucher TM; Gönen M; Cercek A; Kingham TP; Balachandran V; Allen P; DeMatteo R; Drebin J; Jarnagin W; D'Angelica M
    Ann Surg; 2020 Aug; 272(2):352-356. PubMed ID: 32675549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ALPPS Approach for Colorectal Liver Metastases: Impact of KRAS Mutation Status in Survival.
    Serenari M; Alvarez FA; Ardiles V; de Santibañes M; Pekolj J; de Santibañes E
    Dig Surg; 2018; 35(4):303-310. PubMed ID: 29032374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases.
    Karagkounis G; Torbenson MS; Daniel HD; Azad NS; Diaz LA; Donehower RC; Hirose K; Ahuja N; Pawlik TM; Choti MA
    Cancer; 2013 Dec; 119(23):4137-44. PubMed ID: 24104864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathological growth patterns and positive margins after resection of colorectal liver metastases.
    Nierop PMH; Höppener DJ; van der Stok EP; Galjart B; Buisman FE; Balachandran VP; Jarnagin WR; Kingham TP; Allen PJ; Shia J; Vermeulen PB; Groot Koerkamp B; Grünhagen DJ; Verhoef C; D'Angelica MI
    HPB (Oxford); 2020 Jun; 22(6):911-919. PubMed ID: 31735649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.